by Katie Hogan | Apr 8, 2026 | Insights
Patients can’t fully explain their own health decisions. Much of the processing happens before conscious thought, and standard research misses the visceral layer driving the decisions that matter most. The Missing System Kahneman’s System 1 (fast,...
by Katie Hogan | Mar 26, 2026 | Oncology
For decades, oncology has pursued the ‘magic bullet,’ precision therapies that selectively eradicate tumors while sparing healthy tissue. Antibody-drug conjugates (ADCs) are among the closest realizations of that vision. Yet as the pipeline saturates, a new...
by Katie Hogan | Mar 13, 2026 | Insights
A new paper out of Wharton should change how you think about every piece of AI-inclusive research you have run this year. Shaw and Nave ran three preregistered experiments (1,372 participants, over 9,500 trials) and documented something they call “cognitive...
by Katie Hogan | Feb 25, 2026 | Market Access
Author: Alison Kneen, Global Market Access Practice Lead, BioVid Recent developments surrounding U.S. Most Favored Nation (MFN) pricing discussions and the Supreme Court’s ruling limiting tariff authority have largely been covered as isolated legal and political...
by Katie Hogan | Feb 11, 2026 | Market Access
Author: Alison Kneen, Global Market Access Lead, BioVid In the wake of recent geopolitical shifts, Ireland has taken decisive steps to ensure rapid access to innovative medicines, positioning itself as a proactive player in the European healthcare landscape. For...
by Katie Hogan | Feb 11, 2026 | Market Access
Author: Alison Kneen, Global Market Access Practice Lead This year has seen more changes in market access than in the last few decades. The market is moving fast, driven by scientific innovation. Patient expectations are continuing to rise; health budgets are feeling...
